טוען...
Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease
BACKGROUND: Cognitive symptoms are associated with functional disability in Huntington disease; yet, few controlled trials have examined cognitive treatments that could improve patient independence and quality of life. Atomoxetine is a norepinephrine reuptake inhibitor approved for treatment of atte...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3806326/ https://ncbi.nlm.nih.gov/pubmed/19745649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0b013e3181b2ac0a |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|